177 related articles for article (PubMed ID: 17330785)
1. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals.
Biasin M; Piacentini L; Lo Caputo S; Kanari Y; Magri G; Trabattoni D; Naddeo V; Lopalco L; Clivio A; Cesana E; Fasano F; Bergamaschi C; Mazzotta F; Miyazawa M; Clerici M
J Infect Dis; 2007 Apr; 195(7):960-4. PubMed ID: 17330785
[TBL] [Abstract][Full Text] [Related]
2. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
3. Intracellular detection of differential APOBEC3G, TRIM5alpha, and LEDGF/p75 protein expression in peripheral blood by flow cytometry.
Mous K; Jennes W; De Roo A; Pintelon I; Kestens L; Van Ostade X
J Immunol Methods; 2011 Sep; 372(1-2):52-64. PubMed ID: 21784078
[TBL] [Abstract][Full Text] [Related]
4. Expression analysis of LEDGF/p75, APOBEC3G, TRIM5alpha, and tetherin in a Senegalese cohort of HIV-1-exposed seronegative individuals.
Mous K; Jennes W; Camara M; Seydi M; Daneau G; Mboup S; Kestens L; Van Ostade X
PLoS One; 2012; 7(3):e33934. PubMed ID: 22479480
[TBL] [Abstract][Full Text] [Related]
5. APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load.
Reddy K; Winkler CA; Werner L; Mlisana K; Abdool Karim SS; Ndung'u T;
AIDS; 2010 Jan; 24(2):195-204. PubMed ID: 19996938
[TBL] [Abstract][Full Text] [Related]
6. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.
Chen K; Huang J; Zhang C; Huang S; Nunnari G; Wang FX; Tong X; Gao L; Nikisher K; Zhang H
J Virol; 2006 Aug; 80(15):7645-57. PubMed ID: 16840343
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.
Covino DA; Purificato C; Catapano L; Galluzzo CM; Gauzzi MC; Vella S; Lefebvre E; Seyedkazemi S; Andreotti M; Fantuzzi L
Front Immunol; 2018; 9():1839. PubMed ID: 30135687
[TBL] [Abstract][Full Text] [Related]
8. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
9. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
10. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.
Noguera-Julian M; Cozzi-Lepri A; Di Giallonardo F; Schuurman R; Däumer M; Aitken S; Ceccherini-Silberstein F; D'Arminio Monforte A; Geretti AM; Booth CL; Kaiser R; Michalik C; Jansen K; Masquelier B; Bellecave P; Kouyos RD; Castro E; Furrer H; Schultze A; Günthard HF; Brun-Vezinet F; Metzner KJ; Paredes R;
Clin Microbiol Infect; 2016 Feb; 22(2):191-200. PubMed ID: 26482266
[TBL] [Abstract][Full Text] [Related]
11. Protecting APOBEC3G: a potential new target for HIV drug discovery.
Stopak K; Greene WC
Curr Opin Investig Drugs; 2005 Feb; 6(2):141-7. PubMed ID: 15751736
[TBL] [Abstract][Full Text] [Related]
12. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
13. Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance.
Gifford RJ; Rhee SY; Eriksson N; Liu TF; Kiuchi M; Das AK; Shafer RW
AIDS; 2008 Mar; 22(6):717-25. PubMed ID: 18356601
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression.
Vázquez-Pérez JA; Ormsby CE; Hernández-Juan R; Torres KJ; Reyes-Terán G
Retrovirology; 2009 Mar; 6():23. PubMed ID: 19254362
[TBL] [Abstract][Full Text] [Related]
15. Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus.
Peng ZG; Zhao ZY; Li YP; Wang YP; Hao LH; Fan B; Li YH; Wang YM; Shan YQ; Han YX; Zhu YP; Li JR; You XF; Li ZR; Jiang JD
Hepatology; 2011 Apr; 53(4):1080-9. PubMed ID: 21480314
[TBL] [Abstract][Full Text] [Related]
16. An Alu Element Insertion in Intron 1 Results in Aberrant Alternative Splicing of APOBEC3G Pre-mRNA in Northern Pig-Tailed Macaques (
Zhang XL; Luo MT; Song JH; Pang W; Zheng YT
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776266
[TBL] [Abstract][Full Text] [Related]
17. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.
Kim EY; Bhattacharya T; Kunstman K; Swantek P; Koning FA; Malim MH; Wolinsky SM
J Virol; 2010 Oct; 84(19):10402-5. PubMed ID: 20660203
[TBL] [Abstract][Full Text] [Related]
18. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
Peng G; Lei KJ; Jin W; Greenwell-Wild T; Wahl SM
J Exp Med; 2006 Jan; 203(1):41-6. PubMed ID: 16418394
[TBL] [Abstract][Full Text] [Related]
19. Absence of H186R polymorphism in exon 4 of the APOBEC3G gene among North Indian individuals.
Rathore A; Chatterjee A; Yamamoto N; Dhole TN
Genet Test; 2008 Sep; 12(3):453-6. PubMed ID: 18652534
[TBL] [Abstract][Full Text] [Related]
20. [Inhibition of hepatitis B and duck hepatitis B virus replication by APOBEC3G].
Lei YC; Ma T; Hao YH; Zhang ZM; Tian YJ; Wang BJ; Yang DL
Zhonghua Gan Zang Bing Za Zhi; 2006 Oct; 14(10):738-41. PubMed ID: 17064466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
